BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 34539407)

  • 1. Population Pharmacokinetics of Rituximab in Pediatric Patients With Frequent-Relapsing or Steroid-Dependent Nephrotic Syndrome.
    Chen Y; Shen Q; Dong M; Xiong Y; Xu H; Li Z
    Front Pharmacol; 2021; 12():725665. PubMed ID: 34539407
    [No Abstract]   [Full Text] [Related]  

  • 2. Using real-world data to inform dosing strategies of rituximab for pediatric patients with frequent-relapsing or steroid-dependent nephrotic syndrome: a prospective pharmacokinetic-pharmacodynamic study.
    Chen Y; Shen Q; Xiong Y; Dong M; Xu H; Li Z
    Front Pharmacol; 2023; 14():1319744. PubMed ID: 38264525
    [No Abstract]   [Full Text] [Related]  

  • 3. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07).
    Horinouchi T; Sako M; Nakanishi K; Ishikura K; Ito S; Nakamura H; Oba MS; Nozu K; Iijima K
    BMC Nephrol; 2018 Nov; 19(1):302. PubMed ID: 30382824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study protocol: multicenter double-blind, randomized, placebo-controlled trial of rituximab for the treatment of childhood-onset early-stage uncomplicated frequently relapsing or steroid-dependent nephrotic syndrome (JSKDC10 trial).
    Nagano C; Sako M; Kamei K; Ishikura K; Nakamura H; Nakanishi K; Omori T; Nozu K; Iijima K
    BMC Nephrol; 2019 Aug; 20(1):293. PubMed ID: 31375087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials.
    Iijima K; Sako M; Kamei K; Nozu K
    Pediatr Nephrol; 2018 Sep; 33(9):1449-1455. PubMed ID: 28717938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of intravenous immunoglobulin with rituximab versus rituximab alone in childhood-onset steroid-dependent and frequently relapsing nephrotic syndrome: protocol for a multicentre randomised controlled trial.
    Hogan J; Perez A; Sellier-Leclerc AL; Vrillon I; Broux F; Nobili F; Harambat J; Bessenay L; Audard V; Faudeux C; Morin D; Pietrement C; Tellier S; Djeddi D; Eckart P; Lahoche A; Roussey-Kesler G; Ulinski T; Boyer O; Plaisier E; Cloarec S; Jolivot A; Guigonis V; Guilmin-Crepon S; Baudouin V; Dossier C; DeschĂȘnes G
    BMJ Open; 2020 Sep; 10(9):e037306. PubMed ID: 32967877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three-monthly bolus vitamin D supplements (1000 vs 400 IU/day) for prevention of bone loss in children with difficult-to-treat nephrotic syndrome: a randomised clinical trial.
    Singh DN; Krishnamurthy S; Kamalanathan SK; Harichandrakumar KT; Sivamurukan P
    Paediatr Int Child Health; 2018 Nov; 38(4):251-260. PubMed ID: 30092157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial.
    Iijima K; Sako M; Nozu K; Mori R; Tuchida N; Kamei K; Miura K; Aya K; Nakanishi K; Ohtomo Y; Takahashi S; Tanaka R; Kaito H; Nakamura H; Ishikura K; Ito S; Ohashi Y;
    Lancet; 2014 Oct; 384(9950):1273-81. PubMed ID: 24965823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sixteen-week versus standard eight-week prednisolone therapy for childhood nephrotic syndrome: the PREDNOS RCT.
    Webb NJ; Woolley RL; Lambe T; Frew E; Brettell EA; Barsoum EN; Trompeter RS; Cummins C; Wheatley K; Ives NJ
    Health Technol Assess; 2019 May; 23(26):1-108. PubMed ID: 31156083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutational analysis of NPHS2 and WT1 in frequently relapsing and steroid-dependent nephrotic syndrome.
    Gbadegesin R; Hinkes B; Vlangos C; Mucha B; Liu J; Hopcian J; Hildebrandt F
    Pediatr Nephrol; 2007 Apr; 22(4):509-13. PubMed ID: 17216259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab for childhood refractory nephrotic syndrome.
    Iijima K
    Pediatr Int; 2011 Oct; 53(5):617-621. PubMed ID: 21771179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early Rituximab as an Add-On Therapy in Children With the Initial Episode of Nephrotic Syndrome.
    Liu J; Deng F; Wang X; Liu C; Sun S; Zhang R; Zhang A; Jiang X; Yan W; Dou Y; Zhang Y; Xie L; Qian B; Shen Q; Xu H
    Kidney Int Rep; 2024 May; 9(5):1220-1227. PubMed ID: 38707815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab for nephrotic syndrome in children.
    Iijima K; Sako M; Nozu K
    Clin Exp Nephrol; 2017 Apr; 21(2):193-202. PubMed ID: 27422620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunophenotypic Alterations in Adult Patients with Steroid-Dependent and Frequently Relapsing Nephrotic Syndrome.
    Casiraghi F; Todeschini M; PodestĂ  MA; Mister M; Ruggiero B; Trillini M; Carrara C; Diadei O; Villa A; Benigni A; Remuzzi G
    Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab Treatment for Nephrotic Syndrome in Children.
    Iijima K; Sako M; Nozu K
    Curr Pediatr Rep; 2015; 3(1):71-77. PubMed ID: 25741456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and risk factors of rituximab-associated hypogammaglobulinemia in patients with complicated nephrotic syndrome.
    Inoki Y; Kamei K; Nishi K; Sato M; Ogura M; Ishiguro A
    Pediatr Nephrol; 2022 May; 37(5):1057-1066. PubMed ID: 34606002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between HLA alleles and sub-phenotype of childhood steroid-sensitive nephrotic syndrome.
    Lee H; Wang L; Ni FF; Yang XY; Feng SP; Gao XJ; Chi H; Luo YT; Chen XL; Yang BH; Wan JL; Jiao J; Wu DQ; Zhang GF; Wang M; Yang HP; Chan H; Li Q
    World J Pediatr; 2022 Feb; 18(2):109-119. PubMed ID: 34973118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Incidence of hypogammaglobulinaemia in children with steroid-dependent/frequently relapsing nephrotic syndrome treated with rituximab and its association with severe infections].
    Zhi YZ; Cao L; Ying DJ; Dou WJ; Gu R; Zhang JJ
    Zhonghua Yi Xue Za Zhi; 2024 Feb; 104(6):433-439. PubMed ID: 38326055
    [No Abstract]   [Full Text] [Related]  

  • 19. A genomic association study revealing subphenotypes of childhood steroid-sensitive nephrotic syndrome in a larger genomic sequencing cohort.
    Chan H; Ni F; Zhao B; Jiang H; Ding J; Wang L; Wang X; Cui J; Feng S; Gao X; Yang X; Chi H; Lee H; Chen X; Li X; Jiao J; Wu D; Zhang G; Wang M; Cun Y; Ruan X; Yang H; Li Q
    Genes Dis; 2024 Jul; 11(4):101126. PubMed ID: 38560502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab.
    Kamei K; Ishikura K; Sako M; Aya K; Tanaka R; Nozu K; Kaito H; Nakanishi K; Ohtomo Y; Miura K; Takahashi S; Morimoto T; Kubota W; Ito S; Nakamura H; Iijima K;
    Pediatr Nephrol; 2017 Nov; 32(11):2071-2078. PubMed ID: 28664242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.